Production, nano-purification, radiolabeling and biodistribution study of [140Nd] 5,10,15,20-tetraphenylporphyrin complex as a possible imaging agent

Preparation and quality control of a new porphyrin complex labeled with 45Ti for PET imaging

This study aims to produce and quality control of a new porphyrin complex labeled with ⁴⁵Ti for PET imaging, so at the first step, the cross-section of ⁴⁵Sc(p,n)⁴⁵Ti was investigated by TALYS-1.6 and the optimal target thickness and theoretical yield were calculated by SRIM code. The purified ⁴⁵Ti was labeled with the anticancer agent of tetrakis (pentafluorophenyl) porphyrin (TFPP). The radiochemical purity and the percentage of labeling were evaluated by radiation layer chromatography then the division coefficient of [⁴⁵Ti]-TFPP was calculated. The dual coincidence imaging system was used for imaging 1 and 2 h after injection [⁴⁵Ti]-TFPP to rats. Immediately after imaging, the mean percent injected dose per gram and specific activity of different tissues including blood, heart, lungs, stomach, liver, bone, kidney, spleen, intestine, muscle, feces, and skin were measured. The yield of ⁴⁵Ti production was measured 468 MBq/μAh and the labeling rate was observed more than 98%. The highest activity was observed in the liver (%ID/g = 2.27%, 1 h) and spleen (2.2%, 1 h), respectively, because of the high lipophilic of ⁴⁵Ti-TFPP. SPECT images showed a significant uptake of radiopharmaceuticals in the abdomen. The labeling rate of ⁴⁵Ti-TFPP was high and this compound has the potential for clinical application in different ways than PSMA, it can be joined with photodynamic therapy (Severin et al., 2015).

Synthesis and evaluation of radiolabeled porphyrin derivatives for cancer diagnoses and their nonradioactive counterparts for photodynamic therapy

Radioiodinated porphyrin derivatives and the corresponding nonradioactive iodine introduced compounds, [125I]I-TPPOH ([125I]3), [125I]I-l-tyrosine-TPP ([125I]9), I-TPPOH (3), and I-l-tyrosine-TPP (9) were designed, synthesized, and evaluated by in vitro and in vivo experiments. In cytotoxicity assays, 3 and 9 exhibited significant cytotoxicity under light conditions but did not show significant cytotoxicity without light irradiation. Biodistribution experiments with [125I]3 and [125I]9 showed similar distribution patterns with high retention in tumors. In photodynamic therapeutic (PDT) experiments, 3 and 9 at a dose of 13.6 μmol kg-1 weight with 50 W single light irradiation onto the tumor area significantly inhibited tumor growth. These results indicate that the iodinated porphyrin derivatives [123/natI]3 and [123/natI]9 are promising cancer theranostic agents.

Novel radiochromic porphyrin-based film dosimeters for γ ray dosimetry: investigation on metal and ligand effects

As the utilizing of porphyrins and metalloporphyrins in high dose dosimetry becomes more prevalent, research on structural effects of these molecules on dosimetric characteristics and physicochemical properties of their film dosimeters becomes more and more essential. The present study emphasizes dosimetry (measuring radiolytic bleaching of two novel film dosimeters with spectrophotometric methods against 60Co γ-rays exposure in dose range of 0–100 kGy) and evaluating substituent effects on the radiation response of the film dosimeters (role of organic groups and changing the metal core of porphyrins). With casting of solutions of polycarbonate (PC) containing 0.5 wt.% 5,10,15,20-Tetrakis(2,4,6-trimethoxyphenyl) porphyrin (TTMPP) and 5,10,15,20-Tetraphenyl-21H,23H-porphine manganese (III) chloride (Mn-TPP), two novel radiochromic films with the thickness of 20 μm were fabricated. The presence of porphyrin fragments has been observed in the UV–Vis spectra after γ radiation. Due to the changes of the metal core and substituents of the dye ring, meaningful shifts of maximum absorbance of Soret bands of porphyrins and different radiation response of film-dosimeters were observed. The results were compared with the other polycarbonate/porphyrin film dosimeters. The results indicate that the radiation-induced decoloration of PC/Porphyrin films can be reliably tuned and used in high dose dosimetry.

Nuclear medicine for photodynamic therapy in cancer: Planning, monitoring and nuclear PDT

Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. This therapy relies on the effects of light delivered to photosensitized cells. At different stages of delivery, PDT requires imaging to plan, evaluate and monitor treatment. The contribution of molecular imaging in this context is important and continues to increase. In this article, we review the contribution of nuclear medicine imaging in oncology to PDT for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from nuclear medicine imaging. For instance, photosensitizer biodistribution has been evaluated with a radiolabeled photosensitizer or with conventional radiopharmaceuticals on positron emission tomography. The effects of PDT delivery have also been explored with specific SPECT or PET radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. Finally, the synergy between photosensitizers and radiopharmaceuticals has been studied considering the Cerenkov effect to activate photosensitized cells.

PET/PDT theranostics: synthesis and biological evaluation of a peptide-targeted gallium porphyrin

In pursuit of the goal of a molecular theranostic suitable for use as a PET radiotracer and a photosensitiser for PDT, a novel ⁶⁸Ga radiolabelled peptide–porphyrin conjugate targeting the α₆β₁-integrin has been developed.

Synthesis, characterization and in vivo evaluation of [(62)Zn]-benzo-δ-sultam complex as a possible pet imaging agent

OBJECTIVE

The development of a new tracer based on the cyclic sulfonamides (sultams) was investigated.

METHODS

3-(Methoxy-phenyl-methyl)-1,6-dimethyl-1H benzo[c][1,2] thiazine 2,2-dioxide (benzo-δ-sultam) was synthesized and characterized by elemental analysis, FT-IR spectroscopy and single crystal X-ray structure determination. The prepared cyclic sulfonamide was labeled with non-commercial (62)Zn radioisotope for fast in vivo targeting and Coincidence imaging purposes (radiochemical purity 97 % ITLC, 96 % HPLC, specific activity 20-23 GBq/mmol). In vivo biodistribution of the final complex was investigated in Sprague Dawley(®) rats bearing fibro sarcoma tumor after 2, 4 and 8 h post injection and compared with free Zn(+2) cation.

RESULTS

Using instant paper chromatography method, the physicochemical properties of labeled compounds were found sufficiently stable in organic phases, e.g. a human serum, to be reliably used in bioapplications.

CONCLUSIONS

The complex exhibited a rapid as well as high tumor uptake (tumor to blood ratio 4.38 and tumor to muscle ratio 9.63) resulting in an efficient tumor targeting agent.

Radiolabelled porphyrins in nuclear medicine

Amongst tumour-specific substances, hematoporphyrin and synthetic porphyrin derivatives have been widely investigated to identify and delineate neoplastic and malignant tissue. Whilst the tumour localization exhibited by selected porphyrin species has been exploited through photodynamic therapy, several examples of porphyrin derivatives with varied peripheral functionality have been radiolabelled with the aim of developing porphyrin-based nuclear imaging and therapeutic agents. In this review, we look at the approaches and advances in the preparation and uses of such radiolabelled agents for imaging and therapy.